Improved Metabolic Health and Inflammation Balance Semaglutide has been shown to improve insulin resistance and metabolic markers
Some patients see modest improvements in muscle density during treatment
Sources: Raun K, et al
GLP-1 Pipeline Update: February 2025 Quarterly view of the GLP-1 pipeline and anticipated indications Editorial team Maryam Tabatabai, PharmD Editor-In-Chief Associate Vice President, Clinical Information Carole Kerzic, RPh Executive Editor Drug Information Pharmacist Principal Nicole Kjesbo, PharmD, BCPS Executive Editor Clinical Program Development Director Senior, Pipeline DISCLAIMER The drug pipeline is fluid
Customization for Your Brand: Capitalize on private label manufacturing to customize these capsules under your brand, creating a unique and personalized product
Axis 2: Clinical Appropriateness The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy recommends GLP-1 receptor agonist therapy for adults with a BMI of 30 kg/m2 or greater, or a BMI of 27 kg/m2 or greater with at least one weight-related comorbidity, after a structured assessment 11